Vor Biopharma Inc. (VOR)

AI-Powered SEC Filing Analysis

Insider Trading Filed: 2026-04-21

Key Insights

  • RA Capital Management and affiliated entities sold approximately 630,374 shares of VOR stock across two transactions (04/17 and 04/20/2026) at weighted average prices of $16.28 and $15.77, representing a significant reduction in their substantial 10% ownership stake.
  • The selling pattern shows consecutive sales within 3 days at declining prices ($16.28 to $15.77), suggesting either portfolio rebalancing or potential negative sentiment about near-term stock performance.
  • After these sales, RA Capital's beneficial ownership decreased from approximately 2.74 million shares to 2.57 million shares, though they maintain substantial director-level influence through Dr. Andrew Levin on the board.
  • The sales occurred through RA Capital Healthcare Fund LP with multiple tranches at varying prices ($15.95-$16.85 on first date, $15.75-$16.00 on second date), indicating coordinated execution rather than panic selling.
Filing tone (AI): Negative
View Original Filing →
Insider Trading Filed: 2026-04-15

Key Insights

  • RA Capital Management, L.P. and related entities are the beneficial owners of over 10% of Vor Biopharma Inc. (VOR) stock, indicating they have a significant investment in the company.
  • RA Capital Management has been actively selling VOR shares over the past few days, disposing of over 730,000 shares at prices ranging from $15.94 to $16.32.
  • The insider selling activity, while notable, represents only a small portion of RA Capital's overall stake in VOR, suggesting they may still maintain a large position in the company.
Filing tone (AI): Neutral
View Original Filing →
Insider Trading Filed: 2026-04-10

Key Insights

  • Insider trading activity at Vor Biopharma indicates a decline in institutional ownership, with RA Capital Management selling over 600,000 shares across multiple transactions.
  • The reported sales were executed at prices ranging from $15.75 to $16.91 per share, suggesting potential profit-taking by the major institutional investor.
  • The significant reduction in RA Capital's stake from over 4.2 million shares to under 3.9 million shares may signal a shift in their investment thesis or portfolio realignment.
Filing tone (AI): Negative
View Original Filing →
Insider Trading Filed: 2026-04-06

Key Insights

  • RA Capital Management, L.P., a 10% owner of Vor Biopharma Inc. (VOR), has sold a significant number of VOR shares over the past few trading days, indicating potential concerns or a shift in investment strategy.
  • The reported transactions were executed at a range of prices, suggesting that RA Capital may have been taking advantage of price movements to gradually reduce its position in the company.
  • It is worth monitoring whether other major institutional investors follow suit or if RA Capital's actions are an isolated event, as this could signal a broader shift in sentiment towards Vor Biopharma.
Filing tone (AI): Negative
View Original Filing →
Current Report Filed: 2026-01-12

Key Insights

  • Vor Biopharma reported strong cash, cash equivalents and short-term investments of approximately $450 million as of December 31, 2025, indicating a robust financial position.
  • The company will be presenting at the 44th Annual J.P. Morgan Healthcare Conference, providing an opportunity for investor engagement and visibility.
  • The preliminary financial information is subject to change upon completion of the audited financial statements, suggesting investors should await the final results.
Filing tone (AI): Positive
View Original Filing →

Filings on this page are at least 90 days old. In the app, any new Vor Biopharma Inc. filing is analysed the moment you open it.

Download on theApp Store Get it onGoogle Play

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.